IntelGenx Technologies Corp. (IGXT)
| Previous Close | 0.1639 |
| Open | 0.1500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1500 - 0.1690 |
| 52 Week Range | 0.0900 - 0.2200 |
| Volume | |
| Avg. Volume | 90,137 |
| Market Cap | 26.199M |
| Beta (5Y Monthly) | 2.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: IntelGenx Corp.
Announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients ...
GlobeNewswireIntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial. MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progr
- GlobeNewswire
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film. The CRL includes a request for additional Pharmaceutical Q
